hotspot -WSS

hotspot

author：hotspot 2025-10-02 19:20:12 - browse：2

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： IVF, abortion rights issues kick off Biden’s State of the Union

WSS

After Optum profits sink, UnitedHealth makes changes

Biogen’s boardroom scandal saddles CEO with first crisis

Headspace, Meta partner to launch VR meditation app for Quest

First medicine developed to treat MASH expected to be approved soon

Treatments for cramps don't cut it. Why aren't there better options?

Senators push IRS to launch nonprofit hospital probe

entertainment

hotspot

explore

Psychedelics group wrestles with new pharma identity

Megan Rapinoe shares emotional post following US Women's World Cup exit

State Dept. review finds Biden bears some blame for Afghanistan failures

First medicine developed to treat MASH expected to be approved soon

Trump demands the U.S. pay no more for drugs than other countries … again

Dozens dead from Maui wildfires: What we know about the victims

Walensky prepares to leave CDC — and Congress — behind

Biogen’s boardroom scandal saddles CEO with first crisis

As demand for Covid shots wanes, Moderna seeks its next success

Dozens dead from Maui wildfires: What we know about the victims

leisure time

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Change Healthcare payments predicted restored March 15

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Montana youths win climate lawsuit against state for promoting fossil fuels

Patients, digital health players weigh in on FTC's data privacy plan

hotspot

knowledge

focus

Wikipedia